Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
3
Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021
View
Metabolism, Alcohol & Toxicity
3
Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021
View
Metabolism, Alcohol & Toxicity
3
Siemens: Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases - ILC 2021
